MAPT and amyloidosis: Current literature suggest that a substantial proportion of individuals 55 years or older who are not cognitively impaired as assessed from standard cognitive tests still have evidence of amyloid and tau deposition on PET or abnormal CSF consistent with neurodegenerative disease, including AD.